Vetted by NeuralPress's Multi-Agent Verifier for strict factual validity and event relevance. Our compliance engine cross-checks and filters search results to ensure zero false correlations or misleading content.
Primary Sources
Hampshire man calling urgent improvement to cancer diagnosis
A LEUKAEMIA survivor is calling for urgent improvements in how quickly the disease is diagnosed. Ian Thomson, 54, from Winchester, was diagnosed with acute myeloid leukaemia (AML) in June 2019 after experiencing prolonged fatigue, swollen tonsils, and a lump under his arm. Despite visiting his GP twice with these symptoms, he was never given a Full Blood Count test, a simple screening that can help detect leukaemia. His condition deteriorated until his wife took him to A&E, where he was taken to Royal Hampshire County Hospital and finally diagnosed. Mr Thomson said: "I saw my local GP twice, but he didn’t take it seriously. "The symptoms got worse and by June 2019, I’d deteriorated to the point where I couldn’t get out of bed. "It was then that my wife Amanda rushed me to A&E." He was diagnosed with AML, a highly aggressive form of leukaemia that requires immediate treatment. Nearly 80 per cent of people diagnosed with AML in the UK do not survive beyond five years. Mr Thomson underwent six months of intensive chemotherapy and was told that without a stem cell transplant, his chances of survival were low. He received a transplant in February 2020 at Southampton Hospital through the donor register. Ian and wife Amanda meet donor Rachel and her mum (Image: Leukaemia UK) Read More Father and daughter running London Marathon in memory of loved one Conservatives lose control of Hampshire County Council for first time in 30 years Sponsored walk returns to Hampshire in support of breast cancer research Groundbreaking dementia trial underway at Hampshire health trust Father and daughter complete emotional London Marathon in tribute He said: "I’m incredibly fortunate. "I’m back doing everything I did before, but I know how close I came to not being here. "My diagnosis had a profound physical and mental impact on both me and my loved ones. "While the treatment I received was incredible, I’ll never forget how my symptoms were initially dismissed. "I don’t want anyone else to go through that – something needs to change." He later met his donor, Rachel, a nurse from Glasgow, after corresponding anonymously for several years. They have since developed a close friendship. Mr Thomson is backing Leukaemia UK’s Count Us In campaign, which calls for improved access to Full Blood Count tests and clearer referral pathways to prevent delays in diagnosis. Fiona Hazell, chief executive of Leukaemia UK, said: "Ian’s experience is a story that we sadly hea...
Earlier diagnosis, better beginnings for babies with SMA
Project overview The partnership focused on improving understanding of spinal muscular atrophy (SMA) and the importance of early diagnosis through newborn screening. The work took place during a critical period of national policy discussion, when delayed diagnosis continued to have a significant impact on outcomes for babies and their families. SMA UK, the leading national patient organisation for SMA in the UK, played a central role in ensuring patient and family perspectives were responsibly and accurately reflected throughout the activity. By bringing together lived experience, clinical insight and health system evidence, the partnership supported informed, balanced dialogue among policymakers and wider stakeholders. Images provided by SMA UK Finding the right partner Given the sensitivity of newborn screening policy, collaboration needed to be grounded in strong patient legitimacy, independence and credibility. SMA UK was an essential partner. It represents the lived experience of individuals and families affected by the condition and holds long‑standing credibility across the clinical, research and policy landscape. Partnering with SMA UK was vital to ensuring patient and family perspectives were central to the work — not just present but actively shaping how SMA and the impact of delayed diagnosis were understood and discussed. Making contact Novartis UK reviewed the policy context for newborn screening, publicly available evidence, and existing insights into the patient and family experience of SMA. Early conversations focused on understanding SMA UK’s priorities and perspectives, establishing clear boundaries, and aligning on shared principles rather than specific activities. This exploratory phase helped build mutual understanding and trust, supported by regular check‑ins to ensure continued alignment. It provided a strong foundation for partnership activity that remained appropriate, balanced and centred on improving informed dialogue among policymakers and wider stakeholders. Scoping Both partners agreed that the collaboration should be educational in nature, supporting informed understanding of SMA and early diagnosis rather than advocating for predefined policy outcomes. SMA UK played a central role in shaping the scope of activity, drawing on insights from across its community to identify priority themes and ensure patient and family perspectives were embedded from the outset. Flexibility was built into the approach to allow activity to ad...
Cancer care is evolving beyond treatment — towards collaboration ...
Not just a summit, but a gathering of voices working towards a future with better cancer care, stronger support, and more hope. ... early diagnosis can improve ...
The importance of time: Grifols seeks biomarkers for early diagnosis of ...
Grifols is actively seeking biomarkers for early disease detection, prioritising the value of time in diagnosis. Learn more about their initiative Chronos-PD and the importance of timely ...
